Challenges in tackling energy expenditure as obesity therapy: From preclinical models to clinical application
- PMID: 33878401
- PMCID: PMC8122111
- DOI: 10.1016/j.molmet.2021.101237
Challenges in tackling energy expenditure as obesity therapy: From preclinical models to clinical application
Abstract
Background: A chronic imbalance of energy intake and energy expenditure results in excess fat storage. The obesity often caused by this overweight is detrimental to the health of millions of people. Understanding both sides of the energy balance equation and their counter-regulatory mechanisms is critical to the development of effective therapies to treat this epidemic.
Scope of review: Behaviors surrounding ingestion have been reviewed extensively. This review focuses more specifically on energy expenditure regarding bodyweight control, with a particular emphasis on the organs and attractive metabolic processes known to reduce bodyweight. Moreover, previous and current attempts at anti-obesity strategies focusing on energy expenditure are highlighted. Precise measurements of energy expenditure, which consist of cellular, animal, and human models, as well as measurements of their translatability, are required to provide the most effective therapies.
Major conclusions: A precise understanding of the components surrounding energy expenditure, including tailored approaches based on genetic, biomarker, or physical characteristics, must be integrated into future anti-obesity treatments. Further comprehensive investigations are required to define suitable treatments, especially because the complex nature of the human perspective remains poorly understood.
Keywords: Clinical translatability; Energy expenditure; Energy homeostasis; Methodology; Obesity.
Copyright © 2021 The Author(s). Published by Elsevier GmbH.. All rights reserved.
Figures



Similar articles
-
Effect of physical exercise on spontaneous physical activity energy expenditure and energy intake in overweight adults (the EFECT study): a study protocol for a randomized controlled trial.Trials. 2018 Mar 7;19(1):167. doi: 10.1186/s13063-018-2445-6. Trials. 2018. PMID: 29514690 Free PMC article.
-
What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice.Exp Clin Endocrinol Diabetes. 1998;106 Suppl 2:29-34. doi: 10.1055/s-0029-1212034. Exp Clin Endocrinol Diabetes. 1998. PMID: 9792479 Review.
-
Analysis of energy metabolism in humans: A review of methodologies.Mol Metab. 2016 Sep 20;5(11):1057-1071. doi: 10.1016/j.molmet.2016.09.005. eCollection 2016 Nov. Mol Metab. 2016. PMID: 27818932 Free PMC article. Review.
-
Abnormalities of energy expenditure and the development of obesity.Obes Res. 1995 Sep;3 Suppl 2:155s-163s. doi: 10.1002/j.1550-8528.1995.tb00458.x. Obes Res. 1995. PMID: 8581771 Review.
-
Quantification of the effect of energy imbalance on bodyweight.Lancet. 2011 Aug 27;378(9793):826-37. doi: 10.1016/S0140-6736(11)60812-X. Lancet. 2011. PMID: 21872751 Free PMC article.
Cited by
-
The Impact of the Metabolic Syndrome and Its Components on Resting Energy Expenditure.Metabolites. 2022 Aug 5;12(8):722. doi: 10.3390/metabo12080722. Metabolites. 2022. PMID: 36005594 Free PMC article.
-
Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m2 in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist.Diabetes Obes Metab. 2025 Apr;27(4):1773-1782. doi: 10.1111/dom.16167. Epub 2025 Jan 16. Diabetes Obes Metab. 2025. PMID: 39821928 Free PMC article. Clinical Trial.
-
Calopy - an advanced framework for the integration and analysis of indirect calorimetry data.Nat Metab. 2025 Jun;7(6):1093-1095. doi: 10.1038/s42255-025-01316-8. Nat Metab. 2025. PMID: 40562969 No abstract available.
-
Basal metabolic rate shapes the development and progression of hepatocellular carcinoma.BMC Cancer. 2025 Jul 1;25(1):1102. doi: 10.1186/s12885-025-14491-4. BMC Cancer. 2025. PMID: 40598035 Free PMC article.
-
Is Glucagon Receptor Activation the Thermogenic Solution for Treating Obesity?Front Endocrinol (Lausanne). 2022 Apr 25;13:868037. doi: 10.3389/fendo.2022.868037. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35547006 Free PMC article. Review.
References
-
- Müller T., Clemmensen C., Finan B., DiMarchi R., Tschöp M. Anti-obesity therapy: from rainbow pills to polyagonists. Pharmacological Reviews. 2018;70:712–746. - PubMed
-
- Rolfe D., Brown G.C. Cellular energy utilization and molecular origin of standard metabolic rate in mammals. Physiological Reviews. 1997;77:731–758. - PubMed
-
- Tschöp M.H. Unimolecular polypharmacy for treatment of diabetes and obesity. Cell Metabolism. 2016;24:51–62. - PubMed
-
- Geary N. Control-theory models of body-weight regulation and body-weight-regulatory appetite. Appetite. 2020;144:104440. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials